BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Status:
Completed
Trial end date:
2019-08-19
Target enrollment:
Participant gender:
Summary
Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348)
will be asked to participate in this long term extension study with BAY63-2521. The aim of
the long term study is to collect additional information to evaluate the safety and
tolerability of BAY63-2521. Patients will be treated with open label medication on their
individual optimal dose between 0,5 mg - 2,5 mg tid.